

CLEARBRIDGE HEALTH LIMITED

(Company Registration No.: 201001436C)
(Incorporated in the Republic of Singapore)

PROPOSED PLACEMENT OF:

- (A) UP TO 990,000,000 NEW ORDINARY SHARES IN THE CAPITAL OF THE COMPANY AT AN ISSUE PRICE OF S\$0.002 PER PLACEMENT SHARE; AND
 - (B) UP TO 660,000,000 FREE WARRANTS, ON THE BASIS OF TWO (2) WARRANTS FOR EVERY THREE (3) PLACEMENT SHARES, WITH EACH WARRANT CARRYING THE RIGHT TO SUBSCRIBE FOR ONE (1) NEW ORDINARY SHARE IN THE CAPITAL OF THE COMPANY.
 - RECEIPT OF LISTING AND QUOTATION NOTICE
-

1. INTRODUCTION

- 1.1. The board of directors (the “**Board**”) of Clearbridge Health Limited (the “**Company**”) refers to the announcement of the Company dated 4 August 2025 (the “**Placement Announcement**”) in relation to the Proposed Placement cum Warrant Issue.
- 1.2. Unless otherwise defined, all capitalised terms used in this announcement shall bear the same meanings ascribed to them in the Placement Announcement.

2. RECEIPT OF LISTING AND QUOTATION NOTICE

- 2.1. The Board is pleased to announce that the Company has, on 13 August 2025, received the listing and quotation notice from the SGX-ST in relation to the listing of and quotation for up to 990,000,000 Placement Shares and up to 660,000,000 Warrant Shares on the Catalist Board of the SGX-ST (the “**LQN**”). The LQN is subject to the Company’s compliance with the SGX-ST’s listing requirements.
- 2.2. The LQN is not to be taken as an indication of merits of the Proposed Placement cum Warrant Issue, the Placement Shares, the Warrant Shares, the Company and/or its subsidiaries.

3. FURTHER ANNOUNCEMENTS

The Company will continue to keep Shareholders updated and release announcements relating to the Proposed Placement cum Warrant Issue (including any material developments and progress made) as may be appropriate from time to time.

4. CAUTIONARY STATEMENT

Shareholders and potential investors of the Company are advised to read this announcement and any further announcements made by the Company carefully and to exercise caution when dealing in the securities of the Company. Persons who are in doubt as to the action they should take should consult their stockbrokers, bank managers, solicitors or other professional advisers.

By Order of the Board

Yee Pinh Jeremy
Executive Director and Chief Executive Officer

13 August 2025

*This announcement has been reviewed by the Company's sponsor, UOB Kay Hian Private Limited (the "**Sponsor**").*

*This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Mr Lance Tan, Senior Vice President, at 83 Clemenceau Avenue, #10-01 UE Square, Singapore 239920, telephone (65) 6590 6881.